European Journal of Cancer
Volume 48, Issue 3 , Pages 385-388 , February 2012

Poor correlation between progression-free and overall survival in modern clinical trials: Are composite endpoints the answer?

  • Eitan Amir

      Affiliations

    • Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
    • Corresponding Author InformationCorresponding author: Address: Division of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, Toronto, ON, Canada M5G 2M9. Tel.: +1 416 946 4501x5181; fax: +1 416 946 4563.
    • ,
  • Bostjan Seruga

      Affiliations

    • Sector of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
    • ,
  • Ryan Kwong

      Affiliations

    • Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
    • ,
  • Ian F. Tannock

      Affiliations

    • Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
    • ,
  • Alberto Ocaña

      Affiliations

    • Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
    • Albacete University Hospital and AECC Unit, Albacete, Spain

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0959-8049(11)00863-X

doi: 10.1016/j.ejca.2011.10.028

European Journal of Cancer
Volume 48, Issue 3 , Pages 385-388 , February 2012

Article Tools

* Image Usage & Resolution